L

Lineage Cell Therapeutics Inc
TASE:LCTX

Watchlist Manager
Lineage Cell Therapeutics Inc
TASE:LCTX
Watchlist
Price: 382.4 ILS 19.05%
Market Cap: 192.4m ILS
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Loading...
Revenue
Loading...
Operating Income
Loading...
Net Income
Loading...

Wall Street
Price Targets

LCTX Price Targets Summary
Lineage Cell Therapeutics Inc

Wall Street analysts forecast LCTX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for LCTX is 1 300.97 ILS with a low forecast of 493.36 ILS and a high forecast of 3 077.37 ILS.

LCTX Lowest Forecast
Wall Street Target
493.36 ILS
29% Upside
LCTX Average Forecast
Wall Street Target
1 300.97 ILS
240% Upside
LCTX Highest Forecast
Wall Street Target
3 077.37 ILS
705% Upside
Lowest
Price Target
493.36 ILS
29% Upside
Average
Price Target
1 300.97 ILS
240% Upside
Highest
Price Target
3 077.37 ILS
705% Upside
Lineage Cell Therapeutics Inc Competitors:
Price Targets
2616
CStone Pharmaceuticals
31% Downside
K
4584
Kidswell Bio Corporation
24% Upside
ARQT
Arcutis Biotherapeutics Inc
56% Upside
S
688336
Sunshine Guojian Pharmaceutical Shanghai Co Ltd
8% Downside
2616
CStone Pharmaceuticals
31% Downside
K
4584
Kidswell Bio Corporation
24% Upside
ARQT
Arcutis Biotherapeutics Inc
56% Upside
S
688336
Sunshine Guojian Pharmaceutical Shanghai Co Ltd
8% Downside
300896
Imeik Technology Development Co Ltd
31% Upside
ANAB
AnaptysBio Inc
88% Upside
ALT
Altimmune Inc
217% Upside
M
GLUE
Monte Rosa Therapeutics Inc
259% Upside

Revenue
Forecast

Revenue Estimate
Lineage Cell Therapeutics Inc

For the last 8 years the compound annual growth rate for Lineage Cell Therapeutics Inc's revenue is 6%. The projected CAGR for the next 3 years is 78%.

6%
Past Growth
78%
Estimated Growth
Estimates Accuracy
-1%
Average Miss
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Lineage Cell Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-2%
Average Miss
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Lineage Cell Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-31%
Average Miss
What are analyst estimates?

See Also

Summary
LCTX intrinsic value, competitors valuation, and company profile.
DCF Valuation
LCTX stock valuation using Discount Cash Flow valuation method.
Relative Valuation
LCTX stock valuation using valuation multiples.
Wall Street Estimates
LCTX price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
LCTX stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is LCTX's stock price target?
Price Target
1 300.97 ILS

According to Wall Street analysts, the average 1-year price target for LCTX is 1 300.97 ILS with a low forecast of 493.36 ILS and a high forecast of 3 077.37 ILS.

What is Lineage Cell Therapeutics Inc's Revenue forecast?
Projected CAGR
78%

For the last 8 years the compound annual growth rate for Lineage Cell Therapeutics Inc's revenue is 6%. The projected CAGR for the next 3 years is 78%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 263,300+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.